Tempus AI has agreed to acquire Personalis for $16.25 a share in a transaction valuing the genomics company at $1.5 billion, net of Tempus’ existing stake. The consideration is primarily stock, with Tempus retaining the option to fund up to half in cash. Closing is expected in late 2026 or early 2027, subject to shareholder and regulatory approvals.
This is less an adjacency play than a move to own a critical layer of the oncology workflow. Personalis brings tumor-informed molecular residual disease testing, a category that sits downstream of diagnosis and treatment selection and increasingly shapes how clinicians monitor recurrence, adjust therapy, and keep patients inside a testing ecosystem over time. Tempus already sold Personalis’ NeXT Personal assay under a 2023 partnership. Buying the company converts a commercial relationship into vertical control.
That matters because MRD is becoming one of the more contested segments in precision oncology. The value is not only in test revenue. It is in repeat testing, longitudinal patient data, and tighter links between diagnostics, therapy selection, and biopharma research. Tempus has built its pitch around multimodal data and AI. Personalis gives it a stream of high-value serial data from patients after initial treatment, when recurrence risk and intervention decisions become commercially and clinically consequential.
Personalis’ recent operating trajectory helps explain the timing. The company posted preliminary second-quarter revenue of $22.4 million and said clinical test volume rose 33% sequentially to 10,384. For Tempus, that suggests the asset is moving from technical promise toward scaled utilization just as Medicare coverage has opened in three indications and broader reimbursement remains in view.
The premium looks restrained at 6% to the prior close, though 28% to the unaffected 30-day VWAP, reflecting Tempus’ preexisting ownership and the fact that Personalis was already partly embedded in its go-to-market strategy. It also signals a buyer unwilling to overpay for growth in a market where access, evidence generation, and payer behavior still determine winners.
Acquire.fyi data shows technology M&A deal value has climbed 74.5% year to date even as sector volume has fallen 13.4%, a pattern consistent with buyers concentrating capital on fewer assets with clearer strategic utility. Tempus is making that same bet here. Competitors in oncology diagnostics now face a more integrated rival with stronger control over the monitoring phase of cancer care and the data exhaust that comes with it.
Source: Company press release and Acquire.fyi's proprietary data
